30.39
0.41 (1.37%)
| Previous Close | 29.98 |
| Open | 30.21 |
| Volume | 532,783 |
| Avg. Volume (3M) | 923,490 |
| Market Cap | 1,401,656,320 |
| Price / Earnings (Forward) | 84.03 |
| Price / Sales | 7.18 |
| Price / Book | 12.79 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -3.68% |
| Operating Margin (TTM) | -3.42% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | 17.40% |
| Total Debt/Equity (MRQ) | 67.39% |
| Current Ratio (MRQ) | 4.28 |
| Operating Cash Flow (TTM) | 3.62 M |
| Levered Free Cash Flow (TTM) | 2.84 M |
| Return on Assets (TTM) | -0.13% |
| Return on Equity (TTM) | -7.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | AxoGen, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 1.00 |
|
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 4.84% |
| % Held by Institutions | 86.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Mizuho, 31.62%) | Buy |
| 40.00 (Lake Street, 31.62%) | Buy | |
| Median | 37.00 (21.75%) | |
| Low | 27.00 (Raymond James, -11.16%) | Buy |
| Average | 36.14 (18.92%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 29.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 05 Dec 2025 | 37.00 (21.75%) | Buy | 33.32 |
| 30 Oct 2025 | 27.00 (-11.15%) | Buy | 22.68 | |
| HC Wainwright & Co. | 05 Dec 2025 | 39.00 (28.33%) | Buy | 33.32 |
| 30 Oct 2025 | 26.00 (-14.45%) | Buy | 22.68 | |
| Jefferies | 04 Dec 2025 | 36.00 (18.46%) | Buy | 32.86 |
| Lake Street | 04 Dec 2025 | 40.00 (31.62%) | Buy | 32.86 |
| Mizuho | 01 Dec 2025 | 40.00 (31.62%) | Buy | 28.53 |
| Citizens | 30 Oct 2025 | 34.00 (11.88%) | Buy | 22.68 |
| Raymond James | 30 Oct 2025 | 27.00 (-11.15%) | Buy | 22.68 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 |
| 17 Dec 2025 | Announcement | Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference |
| 03 Dec 2025 | Announcement | Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) |
| 04 Nov 2025 | Announcement | Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences |
| 29 Oct 2025 | Announcement | Axogen, Inc. Reports Third Quarter 2025 Financial Results |
| 15 Oct 2025 | Announcement | Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |